Silo Pharma SILO 深 沪
已收盘 10-02 16:00:00 美东时间
1.458
-0.042
-2.80%
华盛通- 最 高1.57
- 今 开1.5004
- 成交量 114.44万股
- 最 低 1.45
- 昨 收 1.50
- 总市值 255.62万
- 52周最高 10.425
- 市盈率 静 --
- 换手率 65.27%
- 52周最低 1.45
- 委 比 97.09%
- 总股本 175.33万
- 历史最高 108.90
- 量 比 17.70
- 振 幅 8.00%
- 历史最低 1.45
- 每 手 1
- 风险率 1.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Silo Pharma Acquires IP Assets in Strategic Agreement
The latest announcement is out from Silo Pharma ( ($SILO) ). On October 1, 2026...
10-03 04:57
Silo Pharma's QwikAgents Subsidiary Expands AI Agent Platform With New Client, To Support Client-Provided Nvidia API Keys, Adds Hermes Agent Runtime
Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent subsidiary QwikAgents, today announced that QwikAgents has expanded its AI agent platform with new custome...
09-30 20:53
Silo Pharma Receives U.S. Patent Office Notice Of Allowance For Application Covering SPC-15, Its Novel Intranasal Therapeutic Targeting Post-Traumatic Stress Disorder
The invention, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior," is also covered by a corresponding patent issued by the Japan Patent Office earlier this year. Silo’s Chief Executive Officer Eric Weisblum commented, "Securing U.S....
09-18 20:52
Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio
Silo Pharma announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, a novel intranasal therapeutic targeting post-traumatic stress disorder (PTSD). The invention, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior,” is also covered by a corresponding patent issued by the Japan Patent Office earl...
09-18 12:50
Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum
Silo Pharma announced its participation in the IPAC-RS 2026 Nasal Innovation Forum to discuss its novel nose-to-brain drug delivery system, SPC-15, for PTSD treatment. The company highlighted preclinical data supporting SPC-15's stability and performance. Silo Pharma focuses on innovative therapies for underserved conditions, leveraging its AI subsidiary, QwikAgents, for research and automation.
09-09 13:15
Silo Pharma Says Canadian Intellectual Property Office Issues Notice Of Allowance For Patent Application Covering SPC-15, Intranasal 5-HT4 Receptor Agonist Targeting PTSD And Other Stress-Induced Psychiatric Disorders
Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program SARASOTA, FLA., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a developmental-stage biopharm...
08-19 04:16
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
Silo Pharma announced that the Canadian Intellectual Property Office has granted a Notice of Allowance for a patent application covering its lead asset, SPC-15, an intranasal 5-HT4 receptor agonist targeting PTSD and other stress-induced psychiatric disorders. The patent, titled "Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress," covers methods of preventing stress-induced fear and enhancing stress resilience. Corresponding p...
08-18 20:15
Silo Pharma’s QwikAgents Engages AWS Premier Tier Services Partner Caylent To Design And Build AWS-Native QwikAgents Platform
Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption SARASOTA, FLA., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a managed AI agent platform and development...
08-06 20:52
Silo Pharma Engages Drug-Device Development Partner Resyca To Carry Out Trial To Evaluate Nasal Spray System For Nose-To-Brain Delivery Of SPC-15 To Treat Post-Traumatic Stress Disorder
Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases, today announced tha...
06-30 04:17
